ChitogenX（CHNX.F）株式概要整形外科とスポーツ医学の生物製剤会社であるChitogenX Inc.は、カナダで整形外科とスポーツ医学の手術の成功率を高めるための新しい治療用軟部組織修復技術の研究開発に従事している。 詳細CHNX.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $303K )株式の流動性は非常に低い マイナスの株主資本 +1 さらなるリスクすべてのリスクチェックを見るCHNX.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0076該当なし内在価値ディスカウントEst. Revenue$PastFuture-5m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesChitogenX Inc. 競合他社Beroni GroupSymbol: OTCPK:BNIG.FMarket cap: US$217.5kLipella PharmaceuticalsSymbol: OTCPK:LIPOMarket cap: US$462.1kSynairgenSymbol: OTCPK:SYGG.FMarket cap: US$110.3kOnconetixSymbol: NasdaqCM:ONCOMarket cap: US$85.9k価格と性能株価の高値、安値、推移の概要ChitogenX過去の株価現在の株価CA$0.007652週高値CA$0.01752週安値CA$0.0011ベータ-2.191ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化-94.83%5年間の変化-97.97%IPOからの変化-98.33%最新ニュースお知らせ • Sep 09ChitogenX Inc. announced that it expects to receive CAD 0.3 million in fundingChitogenX Inc. announced that it has entered into a binding letter of intent for a private placement of secured debentures for a gross proceeds of $300,000 on September 8, 2025. The transaction will include participation from new lender, Oligo Medic.お知らせ • Nov 10Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal StudyChitogenX Inc. announced that ORTHO-R, its proprietary chitosan/PRP based biopolymer matrix, has successfully demonstrated protection from joint degeneration post meniscal repair surgery in a large animal study. In a study of 22 mature sheep, a radial meniscus tear was surgically induced and immediately surgically repaired. The sheep were randomized to three groups: surgery alone,ii) surgery and PRP, and surgery + ORTHO-R and PRP combined. Results were observed 6 months post-surgery. Results showed that the large majority of menisci from the two control groups (surgery alone or surgery + PRP alone) experienced severe structural changes and most control sheep displayed moderate to severe signs of osteoarthritis ("OA"). The medial menisci from the ORTHO-R treated group retained better structure and much milder form of OA and, in some cases, appeared near normal. This study provides the first evidence that treatment with ChitogenX's proprietary chitosan-based biopolymer + PRP prevents structural changes to radially incised and sutured menisci in a large animal model, and most likely contributed to protecting the joints against OA development. This study contributes to a growing and strong body of evidence that the Company's proprietary chitosan -based biopolymer, combined with PRP can potentially bring significant benefit to human tissue repair.お知らせ • Sep 27Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical TrialChitogenX Inc. announced that it has concluded enrolment at 20 subjects in its U.S. multi-site rotator cuff tear repair phase I/II clinical trial entitled: A Blinded, Randomized Controlled Study Investigating the Safety of Ortho-R® for Rotator Cuff Repair Compared with Standard of Care: ORT-2020-01 (Ortho-R® Study). All study activities will be completed by June 2024 as per the clinical trial protocol following completion of the clinical follow-up and safety analysis for the 20 recruited subjects. Study results are expected during the summer of 2024. ChitogenX is grateful to the sites and subjects for their contribution to this important clinical trial. Thus far, there have been no safety issues reported with every subject having been treated between 3 and 12 months. The original U.S. Phase I/II clinical trial protocol was for a blinded, randomized controlled study investigating the safety of ORTHO-R® for rotator cuff tear repair compared with standard of care in a total of 78 subjects at ten clinical sites throughout the U.S. The return on the investment required to complete the full recruitment of the trial is difficult to justify based on the little incremental benefit expected statistically.お知らせ • May 27ChitogenX Inc., Annual General Meeting, Jul 19, 2023ChitogenX Inc., Annual General Meeting, Jul 19, 2023.お知らせ • May 06ChitogenX Inc. announced that it has received CAD 3.856348 million in fundingOn May 5, 2023, ChitogenX Inc. closed the transaction. The company has issued 25,708,988 units at a price of CAD 0.15 per unit for total gross proceeds of CAD 3,856,348.20. The transaction included participation from Insiders for CAD 1,800,000.お知らせ • Feb 15ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus StudyChitogenX Inc. announced that it has successfully confirmed soft-tissue residency properties of its chitosan/PRP based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study. The meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear. It represents the second orthopedic ORTHO-R soft tissue proof of concept application to be successfully confirmed following similar results generated in a previously reported similar study for rotator cuff tear repair.最新情報をもっと見るRecent updatesお知らせ • Sep 09ChitogenX Inc. announced that it expects to receive CAD 0.3 million in fundingChitogenX Inc. announced that it has entered into a binding letter of intent for a private placement of secured debentures for a gross proceeds of $300,000 on September 8, 2025. The transaction will include participation from new lender, Oligo Medic.お知らせ • Nov 10Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal StudyChitogenX Inc. announced that ORTHO-R, its proprietary chitosan/PRP based biopolymer matrix, has successfully demonstrated protection from joint degeneration post meniscal repair surgery in a large animal study. In a study of 22 mature sheep, a radial meniscus tear was surgically induced and immediately surgically repaired. The sheep were randomized to three groups: surgery alone,ii) surgery and PRP, and surgery + ORTHO-R and PRP combined. Results were observed 6 months post-surgery. Results showed that the large majority of menisci from the two control groups (surgery alone or surgery + PRP alone) experienced severe structural changes and most control sheep displayed moderate to severe signs of osteoarthritis ("OA"). The medial menisci from the ORTHO-R treated group retained better structure and much milder form of OA and, in some cases, appeared near normal. This study provides the first evidence that treatment with ChitogenX's proprietary chitosan-based biopolymer + PRP prevents structural changes to radially incised and sutured menisci in a large animal model, and most likely contributed to protecting the joints against OA development. This study contributes to a growing and strong body of evidence that the Company's proprietary chitosan -based biopolymer, combined with PRP can potentially bring significant benefit to human tissue repair.お知らせ • Sep 27Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical TrialChitogenX Inc. announced that it has concluded enrolment at 20 subjects in its U.S. multi-site rotator cuff tear repair phase I/II clinical trial entitled: A Blinded, Randomized Controlled Study Investigating the Safety of Ortho-R® for Rotator Cuff Repair Compared with Standard of Care: ORT-2020-01 (Ortho-R® Study). All study activities will be completed by June 2024 as per the clinical trial protocol following completion of the clinical follow-up and safety analysis for the 20 recruited subjects. Study results are expected during the summer of 2024. ChitogenX is grateful to the sites and subjects for their contribution to this important clinical trial. Thus far, there have been no safety issues reported with every subject having been treated between 3 and 12 months. The original U.S. Phase I/II clinical trial protocol was for a blinded, randomized controlled study investigating the safety of ORTHO-R® for rotator cuff tear repair compared with standard of care in a total of 78 subjects at ten clinical sites throughout the U.S. The return on the investment required to complete the full recruitment of the trial is difficult to justify based on the little incremental benefit expected statistically.お知らせ • May 27ChitogenX Inc., Annual General Meeting, Jul 19, 2023ChitogenX Inc., Annual General Meeting, Jul 19, 2023.お知らせ • May 06ChitogenX Inc. announced that it has received CAD 3.856348 million in fundingOn May 5, 2023, ChitogenX Inc. closed the transaction. The company has issued 25,708,988 units at a price of CAD 0.15 per unit for total gross proceeds of CAD 3,856,348.20. The transaction included participation from Insiders for CAD 1,800,000.お知らせ • Feb 15ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus StudyChitogenX Inc. announced that it has successfully confirmed soft-tissue residency properties of its chitosan/PRP based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study. The meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear. It represents the second orthopedic ORTHO-R soft tissue proof of concept application to be successfully confirmed following similar results generated in a previously reported similar study for rotator cuff tear repair.お知らせ • Feb 10ChitogenX Inc. announced that it expects to receive CAD 6.1 million in fundingChitogenX Inc. announced a best-efforts private placement of 19,333,333 units at an issue price of CAD 0.225 per unit for gross proceeds of up to CAD 4,349,999.925, and non-brokered private placement issue up to 7,777,777 units at an issue price of CAD 0.225 per unit for gross proceeds of up to CAD 1,749,999.825 on February 9, 2023. Each unit will consist of one class A share of the company and one share purchase warrant of the company. Each warrant will entitle the holder to purchase one share of the company at a price of CAD 0.35 per warrant share at any time on or before the date which is 60 months after the closing date of the offering, subject to adjustment in certain events. If, at any time following the date that is 6 months following the closing date, the daily volume weighted average trading price of the shares on the Canadian Securities Exchange is greater than CAD 0.50 per share for the preceding 10 consecutive trading days, the company shall have the right to accelerate the expiry date of the warrants to a date that is at least 30 days following the date of such notice to holders of warrants. The company has granted the agents an option to arrange for the sale of up to an additional 15% of the units at the issue price. The agent’s option may be exercised in whole or in part at any time up to 48 hours prior to the closing date, subject to limitations prescribed by the LIFE exemption. The best-efforts private placement and non-brokered private placement is scheduled to close on or around February 28, 2023, and is subject to certain conditions including, but not limited to, receipt of all necessary approvals including satisfaction of listing conditions of the Canadian Securities Exchange. The closing of the best-efforts private placement is conditional upon the closing of the non-brokered private placement.株主還元CHNX.FUS BiotechsUS 市場7D0%3.1%1.2%1Yn/a34.6%28.7%株主還元を見る業界別リターン: CHNX.FがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: CHNX.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is CHNX.F's price volatile compared to industry and market?CHNX.F volatilityCHNX.F Average Weekly Movementn/aBiotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: CHNX.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCHNX.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2015n/aPierre Laurinwww.chitogenx.com整形外科とスポーツ医学の生物製剤会社であるChitogenX Inc.は、カナダで整形外科とスポーツ医学の手術の成功率を高めるための新しい治療用軟部組織修復技術の研究開発に従事している。腱板修復用バイオポリマーOrtho-R、半月板修復用バイオポリマーOrtho-Mを開発。前身はOrtho Regenerative Technologies Inc.で、2022年9月にChitogenX Inc.に社名変更した。ChitogenX Inc.は2015年に法人化され、カナダのカークランドに本社を置いている。もっと見るChitogenX Inc. 基礎のまとめChitogenX の収益と売上を時価総額と比較するとどうか。CHNX.F 基礎統計学時価総額US$302.75k収益（TTM）-US$1.55m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率CHNX.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CHNX.F 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$1.55m収益-CA$1.55m直近の収益報告Oct 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.019グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-57.5%CHNX.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/15 23:47終値2025/12/17 00:00収益2024/10/31年間収益2024/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ChitogenX Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Gregory AurandNOBLE Capital Markets, Inc.
お知らせ • Sep 09ChitogenX Inc. announced that it expects to receive CAD 0.3 million in fundingChitogenX Inc. announced that it has entered into a binding letter of intent for a private placement of secured debentures for a gross proceeds of $300,000 on September 8, 2025. The transaction will include participation from new lender, Oligo Medic.
お知らせ • Nov 10Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal StudyChitogenX Inc. announced that ORTHO-R, its proprietary chitosan/PRP based biopolymer matrix, has successfully demonstrated protection from joint degeneration post meniscal repair surgery in a large animal study. In a study of 22 mature sheep, a radial meniscus tear was surgically induced and immediately surgically repaired. The sheep were randomized to three groups: surgery alone,ii) surgery and PRP, and surgery + ORTHO-R and PRP combined. Results were observed 6 months post-surgery. Results showed that the large majority of menisci from the two control groups (surgery alone or surgery + PRP alone) experienced severe structural changes and most control sheep displayed moderate to severe signs of osteoarthritis ("OA"). The medial menisci from the ORTHO-R treated group retained better structure and much milder form of OA and, in some cases, appeared near normal. This study provides the first evidence that treatment with ChitogenX's proprietary chitosan-based biopolymer + PRP prevents structural changes to radially incised and sutured menisci in a large animal model, and most likely contributed to protecting the joints against OA development. This study contributes to a growing and strong body of evidence that the Company's proprietary chitosan -based biopolymer, combined with PRP can potentially bring significant benefit to human tissue repair.
お知らせ • Sep 27Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical TrialChitogenX Inc. announced that it has concluded enrolment at 20 subjects in its U.S. multi-site rotator cuff tear repair phase I/II clinical trial entitled: A Blinded, Randomized Controlled Study Investigating the Safety of Ortho-R® for Rotator Cuff Repair Compared with Standard of Care: ORT-2020-01 (Ortho-R® Study). All study activities will be completed by June 2024 as per the clinical trial protocol following completion of the clinical follow-up and safety analysis for the 20 recruited subjects. Study results are expected during the summer of 2024. ChitogenX is grateful to the sites and subjects for their contribution to this important clinical trial. Thus far, there have been no safety issues reported with every subject having been treated between 3 and 12 months. The original U.S. Phase I/II clinical trial protocol was for a blinded, randomized controlled study investigating the safety of ORTHO-R® for rotator cuff tear repair compared with standard of care in a total of 78 subjects at ten clinical sites throughout the U.S. The return on the investment required to complete the full recruitment of the trial is difficult to justify based on the little incremental benefit expected statistically.
お知らせ • May 27ChitogenX Inc., Annual General Meeting, Jul 19, 2023ChitogenX Inc., Annual General Meeting, Jul 19, 2023.
お知らせ • May 06ChitogenX Inc. announced that it has received CAD 3.856348 million in fundingOn May 5, 2023, ChitogenX Inc. closed the transaction. The company has issued 25,708,988 units at a price of CAD 0.15 per unit for total gross proceeds of CAD 3,856,348.20. The transaction included participation from Insiders for CAD 1,800,000.
お知らせ • Feb 15ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus StudyChitogenX Inc. announced that it has successfully confirmed soft-tissue residency properties of its chitosan/PRP based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study. The meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear. It represents the second orthopedic ORTHO-R soft tissue proof of concept application to be successfully confirmed following similar results generated in a previously reported similar study for rotator cuff tear repair.
お知らせ • Sep 09ChitogenX Inc. announced that it expects to receive CAD 0.3 million in fundingChitogenX Inc. announced that it has entered into a binding letter of intent for a private placement of secured debentures for a gross proceeds of $300,000 on September 8, 2025. The transaction will include participation from new lender, Oligo Medic.
お知らせ • Nov 10Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal StudyChitogenX Inc. announced that ORTHO-R, its proprietary chitosan/PRP based biopolymer matrix, has successfully demonstrated protection from joint degeneration post meniscal repair surgery in a large animal study. In a study of 22 mature sheep, a radial meniscus tear was surgically induced and immediately surgically repaired. The sheep were randomized to three groups: surgery alone,ii) surgery and PRP, and surgery + ORTHO-R and PRP combined. Results were observed 6 months post-surgery. Results showed that the large majority of menisci from the two control groups (surgery alone or surgery + PRP alone) experienced severe structural changes and most control sheep displayed moderate to severe signs of osteoarthritis ("OA"). The medial menisci from the ORTHO-R treated group retained better structure and much milder form of OA and, in some cases, appeared near normal. This study provides the first evidence that treatment with ChitogenX's proprietary chitosan-based biopolymer + PRP prevents structural changes to radially incised and sutured menisci in a large animal model, and most likely contributed to protecting the joints against OA development. This study contributes to a growing and strong body of evidence that the Company's proprietary chitosan -based biopolymer, combined with PRP can potentially bring significant benefit to human tissue repair.
お知らせ • Sep 27Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical TrialChitogenX Inc. announced that it has concluded enrolment at 20 subjects in its U.S. multi-site rotator cuff tear repair phase I/II clinical trial entitled: A Blinded, Randomized Controlled Study Investigating the Safety of Ortho-R® for Rotator Cuff Repair Compared with Standard of Care: ORT-2020-01 (Ortho-R® Study). All study activities will be completed by June 2024 as per the clinical trial protocol following completion of the clinical follow-up and safety analysis for the 20 recruited subjects. Study results are expected during the summer of 2024. ChitogenX is grateful to the sites and subjects for their contribution to this important clinical trial. Thus far, there have been no safety issues reported with every subject having been treated between 3 and 12 months. The original U.S. Phase I/II clinical trial protocol was for a blinded, randomized controlled study investigating the safety of ORTHO-R® for rotator cuff tear repair compared with standard of care in a total of 78 subjects at ten clinical sites throughout the U.S. The return on the investment required to complete the full recruitment of the trial is difficult to justify based on the little incremental benefit expected statistically.
お知らせ • May 27ChitogenX Inc., Annual General Meeting, Jul 19, 2023ChitogenX Inc., Annual General Meeting, Jul 19, 2023.
お知らせ • May 06ChitogenX Inc. announced that it has received CAD 3.856348 million in fundingOn May 5, 2023, ChitogenX Inc. closed the transaction. The company has issued 25,708,988 units at a price of CAD 0.15 per unit for total gross proceeds of CAD 3,856,348.20. The transaction included participation from Insiders for CAD 1,800,000.
お知らせ • Feb 15ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus StudyChitogenX Inc. announced that it has successfully confirmed soft-tissue residency properties of its chitosan/PRP based biopolymer matrix, ORTHO-R, in a grant-supported large animal meniscus tear repair study. The meniscus tear repair study confirmed the presence of tissue adherence and the aggregation of PRP regenerative cells imbedded in the tear. It represents the second orthopedic ORTHO-R soft tissue proof of concept application to be successfully confirmed following similar results generated in a previously reported similar study for rotator cuff tear repair.
お知らせ • Feb 10ChitogenX Inc. announced that it expects to receive CAD 6.1 million in fundingChitogenX Inc. announced a best-efforts private placement of 19,333,333 units at an issue price of CAD 0.225 per unit for gross proceeds of up to CAD 4,349,999.925, and non-brokered private placement issue up to 7,777,777 units at an issue price of CAD 0.225 per unit for gross proceeds of up to CAD 1,749,999.825 on February 9, 2023. Each unit will consist of one class A share of the company and one share purchase warrant of the company. Each warrant will entitle the holder to purchase one share of the company at a price of CAD 0.35 per warrant share at any time on or before the date which is 60 months after the closing date of the offering, subject to adjustment in certain events. If, at any time following the date that is 6 months following the closing date, the daily volume weighted average trading price of the shares on the Canadian Securities Exchange is greater than CAD 0.50 per share for the preceding 10 consecutive trading days, the company shall have the right to accelerate the expiry date of the warrants to a date that is at least 30 days following the date of such notice to holders of warrants. The company has granted the agents an option to arrange for the sale of up to an additional 15% of the units at the issue price. The agent’s option may be exercised in whole or in part at any time up to 48 hours prior to the closing date, subject to limitations prescribed by the LIFE exemption. The best-efforts private placement and non-brokered private placement is scheduled to close on or around February 28, 2023, and is subject to certain conditions including, but not limited to, receipt of all necessary approvals including satisfaction of listing conditions of the Canadian Securities Exchange. The closing of the best-efforts private placement is conditional upon the closing of the non-brokered private placement.
